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Abstract
The therapeutic effect of pristine C60 fullerene aqueous colloid solution (C60FAS) on the functioning of the rat soleus
muscle at ischemic injury depending on the time of the general pathogenesis of muscular system and method of
administration C60FAS in vivo was investigated. It was found that intravenous administration of C60FAS is the
optimal for correction of speed macroparameters of contraction for ischemic muscle damage. At the same time,
intramuscular administration of C60FAS shows pronounced protective effect in movements associated with the
generation of maximum force responses or prolonged contractions, which increase the muscle fatigue level.
Analysis of content concentration of creatine phosphokinase and lactate dehydrogenase enzymes in the blood of
experimental animals indicates directly that C60FAS may be a promising therapeutic agent for the prevention and
correction of ischemic-damaged skeletal muscle function.
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Background
Among muscle pathologies that develop in the skeletal
muscles, the ischemic injuries are more than 35% of all in-
juries of musculoskeletal system [1]. Ischemic-reperfusion
injury of skeletal muscle is a major cause of postoperative
pathologic complications [2], particularly, the reason of
amputations and mortality is acute arterial occlusion [3].
Due to the delivery reduction of oxygen in blood flow
through the blood vessels, the nutrients and regulatory
substances cannot reach; thus, the muscle decreases. This
can lead to a progressive disorder in its metabolic, mor-
phological, and physiological processes.
The main aim in the treatment of the ischemic muscles
is the fast recovery of blood flow (reperfusion) in the dam-
aged areas. However, this therapy often leads to new
pathophysiological process; reperfusion injury, which also
can cause significant damage in the muscle tissue.
At ischemic injury of the skeletal muscle, there is a high
correlation between the duration of ischemia and survival
of muscle fiber [4]. Despite the fact that different types of
fibers in the skeletal muscle differ from the metabolic and
functional properties, it has no significant impact on their
tolerance to ischemia-reperfusion injuries [5].
At the biochemical level, the ischemic damage of the
muscle tissue is a sequence of biochemical reactions, which
are initiated by hypoxia after a few minutes of ischemia and
occur independently of etiological features due to insuffi-
cient blood supply to the muscle [1]. The death of the ma-
jority of the muscle cells is a result of chemical substance
activation, which are produced during and after ischemia
and can be formed within a few days even after the restor-
ation of normal blood flow to the muscles.
It is known that after 2 h of skeletal muscle ischemia and
further reperfusion, the concentration of ATP significantly
reduced simultaneously with a significant increase in the
number of lactate from 25 to 114 mmol/kg of dry weight.
And after 3 h of ischemia, the intramuscular supply of ATP
is about 5% from baseline, and glycogen pool is depleted by
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88% [6]. From a functional point of view, these data indi-
cate that a large number of high-energy phosphate com-
pounds in ischemic-damaged muscle cells are spent to
maintain homeostasis (especially during the first hour of is-
chemia) and, consequently, metabolic causes a significant
increase in the fatigue ischemic muscle [7].
It is known that free radicals are a major pathogenic
factor in the development of ischemic damage in the
muscle tissue [8]. Preliminary biological studies of
water-soluble pristine C60 fullerenes [9–13] have shown
that at low (physiological) concentrations, they do not
exhibit acute toxic effects on the normal cells [14–16],
they are not allergenic and immunogenic and they able
to regulate free-radical processes in the cells and tissues,
in particular, neutralize excess free radicals [17, 18].
Consequently, the use of biocompatible and bioavailable
C60 fullerenes as powerful antioxidants [19] opening up
new potential opportunities for the prevention and cor-
rection of ischemic-reperfusion pathological processes in
the muscle tissue.
The purpose of this study was to assess the impact of
water-soluble pristine C60 fullerenes on mechanical and
kinetic peculiarities of rat skeletal muscle function at ische-
mic injury, namely: (1) to conduct a quantitative analysis of
the activity of ischemic-damaged muscle structures and
establish a link between the change in mechano-kinetics of
physiological contractions and the level of C60 fullerenes ac-
tion that is necessary for this change and (2) to evaluate the
therapeutic effect of C60 fullerenes on the time of develop-
ment of general pathogenesis of muscular system depend-
ing on the method of administration (intravenous and
intramuscular) in vivo.
Methods
A highly stable reproducible pristine C60 fullerene aque-
ous colloid solution (C60FAS) in concentration 0.15 mg/
ml was prepared and characterized according to the
protocol [20, 21].
The study was conducted on white male rats of the
“Wistar” line weighing 170 ± 5 g. The animals were kept
under standard conditions in the vivarium of the ESC “In-
stitute of Biology and Medicine”, Taras Shevchenko Na-
tional University of Kyiv. Animals had free access to food
and water. All experiments were conducted in accordance
with the international principles of the European Conven-
tion for protection of vertebrate animals under a control
of the Bio-Ethics Committee of the abovementioned
institution.
All experimental animals were divided into four groups:
intact group (animals with saline injection; n = 10), control
group (animals after ischemia without C60FAS injection;
n = 10), and two experimental groups (animals after ische-
mia with C60FAS injection intravenously (n = 10) and
intramuscularly (n = 10) immediately after reperfusion).
For therapeutic purposes we used C60FAS in a concentra-
tion of 1 mg/kg because this dose was the most effective
at muscular therapy [22, 23].
Anesthesia of animals was performed by intraperitoneal
administration of nembutal (40 mg/kg). For muscle ische-
mia, the branch of the femoral artery of the animal, which
provides blood supply of the experimental muscle, was
dragged by ligatures. Standard preparation of the experi-
ment also included the cannulation (a. carotis communis
sinistra) for the therapeutic administration of C60FAS and
pressure measurement, tracheotomy, and laminectomy at
lumbar spinal cord level. Soleus muscle of rat was released
from the surrounding tissues and its tendon was cut
across in distal part. The ventral roots were cut in places
of their exit from the spinal cord for the modulated stimu-
lation of efferents in L7-S1 segments.
The change in muscle contraction force was measured
using the original strain gages [22, 23]. To generate stimu-
lus signals, the programmable generator of signals of spe-
cial form was used.
The study of dynamic properties of muscle contraction
was performed under conditions of muscle activation using
the modulated stimulation of efferents. Five filaments of
ventral roots were cut and fixed on stimulating electrodes,
and a special device was used for cyclic sequence distribu-
tion of electrical signals via the filaments [22, 23]. The dis-
tributed stimulation was allowed to get the monotonous
and uniform muscle contraction at low stimulation fre-
quency of individual filaments (50 Hz). Stimulation of effer-
ents in L7-S1 segments was performed by electric impulses
of 2 ms, formed by using a pulse generator controlled by
ACC through the platinum electrodes. The parameters of
stimulated signal were programmed and transmitted from
the ACC-CAC complex to generator. A control of external
load on the muscle was carried out with the help of original
mechanical stimulator [23, 24]. The electromagnetic linear
motor was used for perturbation load.
The muscle contraction force was measured at 1, 2, 3,
4, and 5 experimental hours and at 1, 2, 3, 4, and 5 ex-
perimental days after ischemia. All received force curves
reflect the change in the percentage of control values of
the intact muscles, which were taken as 100%.
Level of content of creatine phosphokinase (CPK) and
lactate dehydrogenase (LDH) enzymes in the blood of
experimental animals, as the markers of ischemic injury
of the skeletal muscle, was determined by using a clinical
equipment.
The experimental data were stored and analyzed by stat-
istical processing of the results using standard software
packages Excel and Origin 8.0. All results were expressed
as mean ± SEM. The significance of differences of baseline
values between control and experimental groups was eval-
uated by t test. A value of p < 0.05 was considered statisti-
cally significant.
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Results and Discussion
Biomechanical Study
Kinetics of muscle fatigue and change of the force re-
sponse in each flow of muscle contraction induced by
stimulation successive pools are important characteristics
of the pathogenesis of muscle ischemic injury study.
Under normal conditions, the fatigue changes during the
contraction of the soleus muscle detected only after 5–6 h
stimulation [25].
The main processes, which initiate a cascade of ischemic
pathologies in the damaged muscle, occur in the first
hours after reperfusion [26]. Based on this, the first step in
research is to examine the change in the dynamics of the
contractile process in the first 5 h after reperfusion of the
ischemic soleus muscle. Comparing intravenous and intra-
muscular administration of C60FAS, we tried to determine
the optimal method of its administration to achieve max-
imum therapeutic effect.
Figure 1 shows change in the soleus muscle force
response during the first 5 h after its reperfusion under
activating stimulus pools with duration from 2 to 5 s.
In the control (without affecting C60FAS), reduction of
maximal force responses not only with an increasing time
after ischemia but also with increasing duration of irritating
stimulus signal is observed (Fig. 2). In case of therapeutic
administration of C60FAS, the reduction of force response
with increasing of time irritating signal is negligible and de-
pends mainly on time after reperfusion (Fig. 2). It is
important to note that in this case the method of adminis-
tration of C60FAS had no significant value.
The registration of such important biomechanical par-
ameter as integrated power (it’s calculated by total area,
which describes the force curve) found the similar re-
sults (Fig. 2): the integrated power reduction as with an
increasing time after reperfusion and with increasing
duration stimulation signal is largely compensated by
the influence of C60FAS regardless of its method of ad-
ministration. It is also important to note that the pro-
tective effect of C60FAS manifests on the first hours of
ischemic muscle injury, during which the initiation of
the main stages of ischemic destruction of the muscle
tissue takes place.
Based on the fact that muscle contraction is a dynamic
vibrational process of mutual reactions, one can assume
that in the conditions of pathological changes in muscle fi-
bers caused by ischemia, there should be optimum stimula-
tion parameter ratio, which can involve the maximum
number of sarcomere structures for the optimal muscle
contraction. Although the heterogeneous composition of
skeletal muscle contractile apparatus is difficult to assess
the damage of each individual component, the overall pic-
ture of the pathological process can be traced by measuring
the level of changes of maximum force contraction for sev-
eral days (Figs. 3 and 4). In control, the muscle activity had
a tendency to linear force reduction response with an in-
creasing time after reperfusion that may indicate the
Fig. 1 Force generation curves (F, %) of the ischemic soleus muscle: a control (without affecting C60FAS; n = 10); b intravenous injection of C60FAS
(dose 1 mg/kg; n = 10); c intramuscular injection of C60FAS (dose 1 mg/kg; n = 10). 1, 2, 3, 4, 5 hours after reperfusion of the muscle
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development of muscle fatigue. But unlike the fatigue
process starting from the 2nd day of the experiment, the
force curves contain the pronounced fluctuation compo-
nents. If the power drop is caused by reduction of molecu-
lar generators of power, i.e., by reduction of working cross-
bridges; then, in the case of fluctuation contractions, the
damages should take place in almost all contractile compo-
nents of the muscle cells. So, in this case, one can speak
only about relatively similarity of force responses during fa-
tigue and induced ischemia just in the early stages of patho-
logical process. The significant dependence of dynamic
characteristics of contraction on the activity of the main
types of proprioceptors significantly complicates the control
of the motor activity of the damaged muscle from the cen-
tral nervous system (CNS) in case of uncontrolled fluctu-
ation responses of ischemic-damaged muscle even on a
simple stimulus signal. Elimination of these vibration com-
ponents of muscle contraction with action of C60FAS (re-
gardless of the therapeutic administration method) is a very
important feature of its protective effect (Fig. 3).
With using modulated stimulation, the quantitative and
qualitative differences in the contraction of ischemic rat’s
soleus muscle in control and with C60FAS were observed
(Fig. 4). In control, the value of the maximum force and
integrated power of muscle contraction decreased with an
increasing time after reperfusion as well as the duration of
stimulation (Fig. 4). Therapeutic administration of C60FAS
found the significant protective effect on contraction force
characteristics that were studied as follows: the most pro-
nounced protective effect was observed on the 5th day
after ischemia and at maximum 5 s of stimulation;
C60FAS protective effect on the maximum force response
was 30–35%, and the integrated power—over 50% com-
pared to control. In this case, the difference between pro-
tective effects of C60FAS depending on the method of
administration was observed. Thus, intramuscular injec-
tion of C60FAS showed 10–15% more protective effect on
muscle force response in comparing with the intravenous
administration of C60FAS.
Differences in increasing force and integrated power of
ischemic-injured muscles during intravenous and intra-
muscular administration of C60FAS (Figs. 1, 2, 3, and 4)
indicate the complexity of the molecular mechanisms of
muscle contraction, which are probably different in imple-
menting antioxidant properties of C60 fullerenes. Obvi-
ously, at the therapeutic injection of C60FAS directly into
the damaged muscle, the concentration of C60 fullerenes
are much higher than in the area of inflammation com-
pared with intravenous administration of C60FAS. Thus, it
can be argued on the realization of concentration depend-
ence of the protective effect of C60 fullerenes on the max-
imum force contraction and integrated power of the
ischemic injured muscles.
Observed high correlation between the duration of is-
chemia and muscle fiber survival [4] can be one of the
main factors reducing the maximum force response with
time increasing after ischemia not only due to the de-
crease of muscle fibers survival but also due to the in-
creased rigidity of the muscle (due to an increase of its
Fig. 2 Change of the integrated power S(F) (a) and maximal force of
contraction (F) (b) (as a percentage of control values adopted by
100%) of the ischemic soleus muscle at different duration of
modulated stimulation: 1, 2, 3, 4 stimulation 2, 3, 4, 5 s, respectively;
(○) control (without affecting C60FAS; n = 10); (▲) intravenous
administration of C60FAS (dose 1 mg/kg; n = 10); (●) intramuscular
administration of C60FAS (dose 1 mg/kg; n = 10). 0, 1, 2, 3, 4, 5 hours
after reperfusion muscle. *p < 0.05
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collagen structures). After 3 h of ischemia, the muscle
necrotic changes and nervous degradation occur. The
amount of muscle tissue necrosis may be up to 60%
[27]. In this case, the therapeutic action of C60FAS will
not have a positive effect. Thus, C60FAS, use as a thera-
peutic agent for ischemic muscle damage, will have a
pronounced beneficial effect mainly on the early stages
of this disease.
According to modern theories of motor control in the de-
velopment of muscle pathologies, CNS organizes the limb
movements so as to reduce the number of degrees of free-
dom, which correspond to movements of the individual
segments. The reason for this decrease is the synergies (in-
volving functional activity of intact or partially damaged
muscle fibers), which leads to complications of central
management program movements, thus compromising
control over the implementation of purposeful movements
[28]. Because the structure of the dynamic component of
stimulation (ratio of its amplitude to duration) determines
the speed and range of motion, the changing nature of ef-
ferent activity realization of ischemic muscle results in er-
rors in the positioning accuracy of the joint. By performing
even simple movements, there is a possibility to establish
causal links between the mechanical activity of ischemic-
injured muscles of the joint and key dynamic parame-
ters of movement. The accuracy of this analysis rises
via detailed study of before tetanic areas of muscle
contraction with simultaneous control of mechanical
movement parameters [29]. Therefore, the studying
changes in the dynamics of ischemic-damaged muscle
contraction on before tetanic areas allow to detect
the level of muscle damage and effectiveness of thera-
peutic action of C60FAS.
Figure 5 shows changes in achieving speed of maximum
force response of the ischemic muscle in dependence of
time after ischemia: in the first 5 h and next 5 days after re-
perfusion. In control, after 1 h reperfusion, the reduction of
maximum force and an increase of time to achieve it are
observed. The therapeutic application of C60FAS essentially
adjusts the dynamics of the force curves: a clear separation
of dynamic and stationary parts of the contraction occurs.
It should be noted that this effect is independent of the
manner of C60FAS administration. A more pronounced ef-
fect of C60FAS on before tetanic area muscle contraction
and less on the maximum force response (Fig. 5), in our
opinion, is connected with the beginning of irreversible
pathological changes in the generation of force contraction
on the most vulnerable before tetanic areas in the early
stages of ischemic lesion of muscle cells. This is due to the
uneven destruction of different molecular components of
the contractile apparatus of muscle, which are activated in
different phases of contraction and therefore face different
impact of C60FAS. However, even a slight protective effect
of C60FAS on tetanic areas of muscle contraction is essen-
tial in the first hours after launch of ischemic cascade of
pathological processes and C60 fullerenes have to slow
down their, particularly, neutralizing free radicals in early is-
chemic injury muscle.
Fig. 3 Force generation curves (F, %) of the ischemic soleus muscle: a control (without affecting C60FAS; n = 10); b intravenous injection of C60FAS
(dose 1 mg/kg; n = 10); c intramuscular injection of C60FAS (dose 1 mg/kg; n = 10). 1, 2, 3, 4, 5 days after reperfusion of the muscle
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Research of speed change achieving maximum level of
force within 5 days in control (Fig. 5) found a direct re-
lationship between the speed reduction and time after
reperfusion. Therapeutic administration of C60FAS sig-
nificantly corrected this parameter: its reduction after
the 1st day after ischemia was not changed significantly
over the next 4 days of experiment. Intravenous admin-
istration of C60FAS demonstrated better protective effect
(on 10%) compared to intramuscular administration of
C60FAS.
Biochemical Study
Most characteristic biochemical compounds which, on
the one hand, easily identified in clinical conditions and,
on the other hand, the content of which changes signifi-
cantly upward in patients with ischemic injuries, are
CPK and LDH [30].
CPK is contained in high concentration in the skeletal
muscles, and body consumes it rapidly by increasing phys-
ical activity. If the damage of myocytes happens, CPK dif-
fuses from them, thus increasing its activity in the blood.
Therefore, determining the activity of CPK in the blood is a
sensitive diagnostic test for the manifestation of ischemic
damage in the muscle tissue [31].
Fig. 5 Change of speed attaining maximum force response (ΔF, %)
of the ischemic soleus muscle: (○) control (without affecting C60FAS;
n = 10), (▲) intravenous injection of C60FAS (dose 1 mg/kg; n = 10),
(●) intramuscular injection of C60FAS (dose 1 mg/kg; n = 10). 1 and 2
hours and days, respectively, after reperfusion of the
muscle. *p < 0.05
Fig. 4 Change of the integrated power S(F) (a) and maximal force of
contraction (F) (b) (as a percentage of control values adopted by
100%) of the ischemic soleus muscle at different duration of
modulated stimulation: 1, 2, 3, 4 stimulation 2, 3, 4, 5 s, respectively;
(○) control (without affecting C60FAS; n = 10); (▲) intravenous
administration of C60FAS (dose 1 mg/kg; n = 10); (●) intramuscular
administration of C60FAS (dose 1 mg/kg; n = 10). 0, 1, 2, 3, 4, 5 days
after reperfusion of the muscle. *p < 0.05
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LDH participates in the processes of oxidation of glu-
cose and the formation of lactic acid. It is contained in al-
most all organs and tissues of the human, especially a lot
of it in the muscles. In the conditions of hypoxia, LDH
causes a feeling of muscle fatigue and breaks the process
of tissue breathing. Blood tests for CPK and LDH used in
the clinic for the rapid identification of diseases associated
with ischemic injuries of the muscular system [32].
Determination of the levels of these enzymes in the blood
of tested animals showed accurate tendency to their re-
duction after therapeutic administration of C60FAS after
the first 5 h (Fig. 6) and 5 days after ischemia (Fig. 7).
Considering that at ischemic injury of the skeletal
muscle, the reactive oxygen species (ROS) are of the
most destructive danger, the use of C60 fullerenes as
powerful antioxidants should significantly improve
muscle tolerance to ischemia and expedite postoperative
recovery [33].
The observed effects above may be related to the fact that
2 h ischemia-reperfusion of the soleus muscle significantly
reduces the concentration of ATP with significant increase
in lactate. It is known that, for a 3 h ischemia, ATP deple-
tion is about 95%, and glycogen depletion is 88% [6, 7]. In
addition, a large number of high-energy phosphates are
spent by the damaged muscle cell to maintain hemostasis
and, as a result, the metabolic disorder leads to greater
muscle fatigue. At the same time, literature data indicate
that ROS (for example, superoxide anion and hydroxyl rad-
ical) are a major pathogenic factor in ischemia-reperfusion
tissue damage. ROS initiate the lipid peroxidation, direct
inhibition of mitochondrial respiratory chain enzymes, in-
activation of glyceraldehyde-3-phosphate dehydrogenase,
ATPase inhibition activity, inactivation of membrane so-
dium channels, etc. It was shown that modified C60 fuller-
enes can be considered as a powerful ROS absorber of
ischemia-reperfusion-induced injury of small intestine [34].
Fig. 6 Change in the content of creatine phosphokinase (1) and lactate dehydrogenase (2) in the ischemic soleus muscle 5 h after reperfusion:
a intact animals (n = 10), b control (without affecting C60FAS; n = 10); c intravenous injection of C60FAS (dose 1 mg/kg; n = 10); d intramuscular
injection of C60FAS (dose 1 mg/kg; n = 10). *p < 0.05
Fig. 7 Change in the content of creatine phosphokinase (1) and lactate dehydrogenase (2) in the ischemic soleus muscle after 5 days after
reperfusion: a intact animals (n = 10), b control (without affecting C60FAS; n = 10), c intravenous injection of C60FAS (dose 1 mg/kg; n = 10),
d intramuscular injection of C60FAS (dose 1 mg/kg; n = 10). *p < 0.05
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Also, the ability of C60 fullerene derivatives to reduce the
ischemia-reperfusion lung injury was demonstrated [35,
36]. In this regard, the protective effect of C60FAS on the
fatigue processes of the ischemic-damaged muscle can be
directly linked to the strong antioxidant properties of
pristine C60 fullerenes.
Conclusions
The results of this study can be united in the following
paragraphs:
1. A pronounced protective effect of C60FAS on the
contractile dynamics of muscle soleus ischemic
injury was reliably established.
2. It was shown that intravenous and intramuscular
injections of C60FAS have different therapeutic
effects: the intravenous injection of C60FAS is
optimal for correction of speed macroparameters of
contraction at ischemic muscle damage; the
intramuscular injection of C60FAS demonstrates
more pronounced protective effect in movements
associated with the generation of maximum force
responses or prolonged contractions caused by
increasing levels of muscle fatigue. It must be
emphasized that protective effect of C60FAS is also
important to correct the accuracy of the joint
position of the injured limb, since for precision
positioning and fine motor skills of limbs, extremely
important is the ability to hold the tetanic
contraction regime by the antagonist muscles, the
implementation of which is lost during ischemic
pathology.
3. The use of biocompatible water-soluble pristine C60
fullerenes considering prominent antioxidant prop-
erties and lack of data of acute and chronic toxicity
open new possibilities in the therapy and prevention
of ischemic pathologies.
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